General Catalyst Group Management LLC purchased a new position in Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) in the first quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 1,035,910 shares of the company's stock, valued at approximately $11,405,000. Maze Therapeutics accounts for 1.3% of General Catalyst Group Management LLC's portfolio, making the stock its 8th largest holding. General Catalyst Group Management LLC owned 2.37% of Maze Therapeutics as of its most recent filing with the SEC.
Maze Therapeutics Stock Performance
Maze Therapeutics stock traded down $0.15 during trading hours on Friday, hitting $13.40. The company had a trading volume of 100,659 shares, compared to its average volume of 226,841. The company's fifty day moving average is $10.13. Maze Therapeutics, Inc. has a fifty-two week low of $6.71 and a fifty-two week high of $17.00.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.39).
Wall Street Analyst Weigh In
Several analysts recently commented on MAZE shares. Leerink Partnrs raised shares of Maze Therapeutics to a "strong-buy" rating in a research note on Tuesday, February 25th. JPMorgan Chase & Co. started coverage on shares of Maze Therapeutics in a research note on Tuesday, February 25th. They set an "overweight" rating and a $30.00 target price for the company. Guggenheim reissued a "buy" rating and set a $19.00 target price on shares of Maze Therapeutics in a research note on Wednesday, April 2nd. TD Cowen upgraded shares of Maze Therapeutics to a "strong-buy" rating in a report on Tuesday, February 25th. Finally, Leerink Partners assumed coverage on shares of Maze Therapeutics in a report on Tuesday, February 25th. They set an "outperform" rating and a $28.00 price target on the stock. Three analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $25.67.
Get Our Latest Analysis on Maze Therapeutics
About Maze Therapeutics
(
Free Report)
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
Featured Articles
Before you consider Maze Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.
While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
